RGNX

Regenxbio Inc

7.20

Oct 30 • 3:59 PM ET -0.21 (-2.83%)

7.20

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: SLDB SRPT FDMT RARE DNLI QURE RCKT DYN TSHA OCGN

| Held by: XBI VTI IWM VXF FESM IBB IWO VTWO SCHA VHT

Scroll to Statements

Index	RUT
Market Cap	475.30M
Enterprise Value	620.02M
Income	-196.43M
Sales	174.48M
Book/sh	1.32
Cash/sh	1.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	371
IPO	Sep 17, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	2.72
P/B	5.43
P/C	4.49
P/FCF	-
EV/EBITDA	-
EV/Sales	3.55
Quick Ratio	2.86
Current Ratio	2.86
Debt/Eq	3.49
LT Debt/Eq	3.01
Option/Short	Yes / Yes

EPS (ttm)	-3.79
EPS next Y	-2.74
EPS next Q	-1.29
EPS this Y	8.16%
EPS next Y	20.66%
EPS next 5Y	24.29%
EPS past 3/5Y	16.67% -4.73%
Sales past 3/5Y	14.78% 1.97%
EPS Y/Y TTM	-9.21%
Sales Y/Y TTM	12.00%
EPS Q/Q	131.11%
Sales Q/Q	405.73%
Earnings	Nov 05 BMO
EPS/Sales Surpr.	446.38% 10.64%

Insider Own	7.51%
Insider Trans	0.58%
Inst Own	63.72%
Inst Trans	1.84%
ROA	-40.60%
ROE	-137.63%
ROIC	-68.18%
Gross Margin	77.57%
Oper. Margin	-94.08%
Profit Margin	-112.58%
SMA20	-1.07%
SMA50	-9.80%
SMA200	-21.49%
Trades

Shs Outstand	66.01M
Shs Float	61.06M
Short Float	16.45%
Short Ratio	7.40
Short Interest	10.04M
52W High	16.19 -55.53%
52W Low	5.45 31.99%
Volatility	7.35% 6.63%
ATR (14)	0.49
RSI (14)	46.42
Beta	1.24
Rel Volume	0.78
Avg Volume	1.36M
Volume	1,061,536

Perf Week	7.78%
Perf Month	-2.96%
Perf Quarter	-27.71%
Perf Half Y	-21.05%
Perf YTD	-50.00%
Perf Year	-43.84%
Perf 3Y	-49.90%
Perf 5Y	-79.68%
Perf 10Y	-54.72%
Recom	1.36
Target Price	22.91
Prev Close	7.41
Price	7.20
Change %	-2.83%

Consensus

Strong Buy

Avg. Price Target

$22.91

Implied Upside

+218.2%

Analysts14incl. previous ratings

Rating Distribution11 Buy · 3 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 05, 2026	Initiated	MMizuho	Outperform	$22	+205.6%
Aug 07, 2026	Downgrade	BBarclays	Overweight → Equal Weight	$12	+66.7%
Jan 28, 2026	Resumed	BBarclays	Overweight	$37	+413.9%
Feb 11, 2025	Downgrade	GGoldman	Buy → Neutral	$38 → $14	+94.4%
Feb 07, 2025	Resumed	RRaymond James	Outperform	$27	+275.0%
Nov 15, 2024	Resumed	MMorgan Stanley	Overweight	$22	+205.6%
Oct 10, 2024	Resumed	RRaymond James	Outperform	$18	+150.0%
Jun 07, 2024	Initiated	GGoldman	Buy	$38	+427.8%
Mar 11, 2024	Initiated	HH.C. Wainwright	Buy	$36	+400.0%
Mar 08, 2024	Upgrade	RRBC Capital Mkts	Sector Perform → Outperform	$20 → $35	+386.1%
Mar 06, 2024	Upgrade	LLeerink Partners	Market Perform → Outperform	$37	+413.9%
Feb 21, 2024	Resumed	RRaymond James	Outperform	$45	+525.0%
Nov 01, 2023	Initiated	SStifel	Buy	$35	+386.1%
Jun 02, 2023	Initiated	RRobert W. Baird	Outperform	$42	+483.3%
Jun 23, 2022	Initiated	BBerenberg	Buy	$61	+747.2%
Dec 15, 2021	Initiated	WWedbush	Neutral	$29	+302.8%
Oct 19, 2021	Resumed	MMorgan Stanley	Overweight	$62 → $50	+594.4%
Jan 06, 2021	Upgrade	RRaymond James	Outperform → Strong Buy	$60	+733.3%
Dec 16, 2020	Initiated	UUBS	Buy	$57	+691.7%
Jun 25, 2020	Resumed	BBofA/Merrill	Buy	$9	+25.0%

Oct-29-26 12:01PM	REGENXBIO Faces A Filing Checkpoint As Royalties Shrink And The Stock Slumps (Earnings Whispers)
07:05AM	REGENXBIO to Host Conference Call on November 5 to Discuss Third Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Oct-12-26 07:05AM	REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20 (PR Newswire)
Oct-05-26 09:44AM	Microsoft upgraded, HubSpot downgraded: Wall Street's top analyst calls (The Fly)
07:42AM	Regenxbios Two Lead Gene Therapies Back Mizuhos Nearly 200% Upside Call (Stocktwits)
09:37AM	Loading…
Sep-25-26 09:37AM	Regenxbio stock gains on positive gene therapy trial data (Investing.com)
Sep-24-26 07:17PM	REGENXBIO Presents Positive Three-Year Durability Data for Surabgene Lomparvovec in Diabetic Retinopathy at Retina Society Annual Scientific Meeting (PR Newswire)
Sep-16-26 05:30AM	Trump Administration Shift Puts This Corner of Biotech Back in Favor (The Wall Street Journal)
Sep-08-26 07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Aug-25-26 07:05AM	REGENXBIO Strengthens Board of Directors with Appointment of Greg Ciongoli (PR Newswire) +10.61%
06:50AM	Regenxbios RGX-121 Setback Carries A Potential Cash Risk, Warns Clear Street (Stocktwits)
06:21AM	FDA places clinical hold on REGENXBIOs RGX-121 in MPS II trial (Hospital Management)
Aug-24-26 03:18PM	RGNX Stock On Track For Worst Day In Over Three Months BofA Says Buy Despite Disappointing FDA Hold On Gene Therapy (Stocktwits) -24.86%
10:18AM	Why Regenxbio Halted Its Gene Therapy Trial-and Why the Stock Is Tumbling (Barrons.com)
09:02AM	Why Did RGNX Stock Crash Today? (Stocktwits)
08:45AM	Loading…
08:45AM	REGENXBIO Shares Plunge After FDA Places Clinical Hold on RGX-121 (InvestorsHub)
08:39AM	Regenxbio Stock Sinks 22% Following Surprise Finding in Gene Therapy Trial (Barrons.com)
07:55AM	Safety concerns spur FDA to again halt testing of Regenxbio gene therapy (BioPharma Dive)
07:05AM	REGENXBIO Announces Regulatory Update on RGX-121 for MPS II (PR Newswire)
Aug-06-26 03:02PM	Regenxbio Inc (RGNX) (Q2 2026) Earnings Call Highlights: Cash Runway Extended into Q4 2027 on ... (GuruFocus.com) +7.43%
07:22AM	Regenxbio: Q2 Earnings Snapshot (Associated Press)
07:05AM	REGENXBIO Reports Second Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Aug-03-26 07:05AM	REGENXBIO to Host Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
Jul-18-26 02:55PM	REGENXBIO Presents Positive Long-Term Data for Surabgene Lomparvovec in Wet AMD and Diabetic Retinopathy at American Society of Retina Specialists Annual Meeting (PR Newswire)
Jul-17-26 07:00AM	REGENXBIO Announces Pricing of Public Offering of Common Stock and Pre-funded Warrants (PR Newswire) -11.70%
Jul-16-26 06:36PM	RGNX Stock Slumps 15% After-Hours Whats Driving The Selloff? (Stocktwits) -8.72%
04:26PM	REGENXBIO Announces Proposed Public Offering of Common Stock (PR Newswire)
Jun-29-26 07:05AM	REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone (PR Newswire) +12.88%
Jun-24-26 07:05AM	REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 (PR Newswire)
Jun-23-26 10:26AM	FDA changes rare disease tune again as it clears path for Regenxbios gene therapy (Pharmaceutical Technology) +9.70%
11:12AM	Loading…
Jun-22-26 11:12AM	AbbVie's Deal with Apogee; Regenxbio Moves on Gene Therapy Drug \| Stock Movers (Bloomberg) +16.28%
08:44AM	RGNX Retail Investors See Hope As FDA Reopens Door For Regenxbios Hunter Syndrome Therapy (Stocktwits)
07:39AM	Regenxbio to resubmit gene therapy as FDA backtracks on another drug rejection (BioPharma Dive)
07:30AM	REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II (PR Newswire)
06:30AM	FDA Will Reverse Rejection of Third Rare-Disease Drug, Regenxbio Says (The Wall Street Journal)
May-18-26 04:05PM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
May-14-26 07:03PM	Regenxbio Inc (RGNX) Q1 2026 Earnings Call Highlights: Promising RGX-202 Results and Path to ... (GuruFocus.com) -37.80% -8.41%
10:09AM	Regenxbio Shares Rise After Positive Duchenne Trial Results (InvestorsHub)
07:18AM	Regenxbio: Q1 Earnings Snapshot (Associated Press)
07:10AM	REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights (PR Newswire)
07:00AM	REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE Study of RGX-202 (PR Newswire)
05:10AM	With new data, Regenxbio to seek FDA approval of Duchenne gene therapy (BioPharma Dive)
May-07-26 07:05AM	REGENXBIO Announces Presentations at the American Society of Gene & Cell Therapy 2026 Annual Meeting (PR Newswire)
May-06-26 07:05AM	REGENXBIO to Host Webcast on May 14 to Discuss Topline Results from Pivotal Trial of RGX-202 for Duchenne Muscular Dystrophy (PR Newswire) +10.85%
Apr-01-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-30-26 04:06AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Mar-26-26 09:00AM	SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD (PR Newswire)
Mar-25-26 02:11PM	Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval (Investor's Business Daily) +8.32%
05:01AM	Mixed signals cloud the orphan drug market (Pharma Voice)
Mar-24-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire) -6.35%
Mar-19-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST, LLP (PR Newswire)
Mar-17-26 04:00PM	Stephen Pakola Oversaw RGX-111 Safety Claims That Cost RGNX Investors Millions: Levi & Korsinsky, LLP (Business Wire)
Mar-12-26 09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: SUEWALLST (PR Newswire)
Mar-11-26 11:45AM	REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE TRIAL OF RGX-202 (PR Newswire) -5.25%
09:00AM	STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP (PR Newswire)
Mar-10-26 04:00PM	RGNX's Inadequate Risk Disclosures Allegedly Cost Investors $2.40/Share: Levi & Korsinsky, LLP (Business Wire)
Mar-09-26 04:37PM	This biotech's stock soared after a 'polarizing' FDA official is stepping down (MarketWatch) +20.00%
01:32PM	What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? (Benzinga)
01:15PM	Biotech Stocks Rally on Departure of Polarizing FDA Official (The Wall Street Journal)
08:23AM	uniQure stock surges 36% on FDA officials departure (Investing.com)
Mar-06-26 05:56PM	FDA vaccine chief Vinay Prasad set to leave post next month (Bloomberg)
12:10AM	REGENXBIO Q4 Earnings Call Highlights (MarketBeat)
Mar-05-26 02:25PM	RGNX'S "TRANSFORMATIONAL" PROMISE BECAME A $2.40 LOSS FOR INVESTORS: SUEWALLST (PR Newswire)
02:02PM	Regenxbio Inc (RGNX) Q4 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience (GuruFocus.com)
08:25AM	Regenxbio (RGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:23AM	Regenxbio: Q4 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire)
Mar-04-26 09:00AM	REGENXBIO Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - RGNX (PR Newswire) +5.18%
07:05AM	REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference (PR Newswire)
Mar-03-26 05:30AM	MAHA Is Bringing Chaos to Biotech Investment Beyond Just Vaccines (The Wall Street Journal) -5.95%
Mar-02-26 05:58PM	REGENXBIO, Inc. Stockholders Have Rights - Stockholders Who Lost Money Investing in RGNX Should Contact Robbins LLP for Information About Recovering Their Losses (PR Newswire)
10:00AM	Adherex Technologies Inc. (FENC) Earnings Expected to Grow: What to Know Ahead of Q4 Release (Zacks)
07:05AM	REGENXBIO to Participate in Upcoming Investor Conferences (PR Newswire)
Feb-27-26 12:49AM	QURE Or RGNX: Which Gene Therapy Was FDA Chief Really Warning About In Rare Disease Remarks? (New feeds test provider finance)
Feb-26-26 04:06PM	Uniqure Plummets As FDA's Marty Makary Disparages Rejected Rare Disease Drug (Investor's Business Daily)
10:00AM	Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Feb-25-26 07:05AM	REGENXBIO to Host Conference Call on March 5 to Discuss Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights (PR Newswire) +5.57%
Feb-20-26 04:19AM	REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX (PR Newswire)
Feb-17-26 07:30AM	REGENXBIO Inc. Sued for Securities Law Violations Contact the DJS Law Group to Discuss Your Rights RGNX (Business Wire)
Feb-10-26 08:51AM	FDA Rejection Clouds Path For REGENXBIO's Rare Disease Treatment (Benzinga) -14.16%
06:19AM	FDA rejects Regenxbio treatment in another blow to gene therapy (BioPharma Dive)
05:49AM	REGENXBIO receives FDA response for RGX-121 application (Pharmaceutical Business Review)
Feb-09-26 04:05PM	REGENXBIO Announces Regulatory Update on RGX-121 BLA for MPS II (PR Newswire)
Feb-02-26 12:18AM	Lost Money on REGENXBIO Inc. (RGNX)? Possible Fraud - Contact Levi & Korsinsky Today (Newsfile)
Jan-30-26 06:40AM	Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock? (Zacks)
Jan-29-26 10:10AM	Regenxbio selloff an overreaction to clinical hold, says Leerink (TipRanks) +5.36%
Jan-28-26 12:31PM	FDA Clinical Hold Knocks REGENXBIO Stock (Benzinga) -17.90%
09:22AM	The 'Confusing And Unexpected' Update That Slammed Regenxbio Stock (Investor's Business Daily)
07:30AM	REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs (PR Newswire)
06:06AM	Regenxbio gene therapy trials suspended by FDA over safety worries (BioPharma Dive)
Jan-26-26 02:49PM	Sarepta Stock Climbs. 3-Year Study Results for Elevidys Bring Hope. (Barrons.com)
Jan-19-26 05:20PM	REGENXBIO Inc. (RGNX): A Bull Case Theory (Insider Monkey)
Jan-11-26 03:00PM	REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program (PR Newswire)
Dec-18-25 07:05AM	REGENXBIO to Present at the 44th Annual J.P. Morgan Healthcare Conference (PR Newswire)
Nov-25-25 07:05AM	REGENXBIO to Participate in Upcoming Investor Conference (PR Newswire) +9.98%
Nov-06-25 02:08PM	Regenxbio Inc (RGNX) Q3 2025 Earnings Call Highlights: Strong Financial Position and Strategic ... (GuruFocus.com)
08:25AM	Regenxbio (RGNX) Reports Q3 Loss, Beats Revenue Estimates (Zacks)
07:25AM	Regenxbio: Q3 Earnings Snapshot (Associated Press Finance)
07:05AM	REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights (PR Newswire)
Oct-30-25 07:05AM	REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Ciongoli Gregory Austin	Director	Aug 27 '26	Buy	9.36	53,407	499,676	118,035	Aug 27 07:03 PM
Ciongoli Gregory Austin	Director	Aug 26 '26	Buy	9.14	49,196	449,706	64,628	Aug 27 07:03 PM
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Option Exercise	7.86	2,161	16,985	215,170	Jul 06 04:51 PM
PAKOLA STEVE	Chief Medical Officer	Jul 02 '26	Sale	13.64	2,161	29,476	213,009	Jul 06 04:51 PM
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Option Exercise	7.86	36,725	288,658	249,734	Jul 01 08:08 PM
PAKOLA STEVE	Chief Medical Officer	Jul 01 '26	Sale	12.86	36,725	472,284	213,009	Jul 01 08:08 PM
PAKOLA STEVE	Chief Medical Officer	Jun 29 '26	Sale	11.04	19,608	216,472	213,009	Jul 01 08:08 PM
Stephen J. Pakola	Officer	Jul 01 '26	Proposed Sale	11.98	43,206	517,608		Jul 01 04:30 PM
PAKOLA STEVE	Chief Medical Officer	May 11 '26	Sale	11.02	15,309	168,705	232,617	May 13 05:18 PM
STEPHEN PAKOLA	Officer	May 11 '26	Proposed Sale	10.55	34,917	368,374		May 11 04:36 PM
PAKOLA STEVE	Chief Medical Officer	Mar 10 '26	Sale	10.35	5,124	53,033	247,926	Mar 12 06:17 PM
STEPHEN J PAKOLA	Officer	Mar 10 '26	Proposed Sale	10.38	5,124	53,187		Mar 10 04:36 PM
Mills Kenneth T.	Director	Jan 27 '26	Option Exercise	13.09	225,000	2,945,250	707,871	Jan 29 04:58 PM

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Executive VP & Chief Medical OfficerDr. Stephen Pakola M.D.

Executive VP & CFOMr. Mitchell Chan M.B.A.

Executive VP of Product Development & CTOMr. Craig Malzahn

Executive VP & Chief Scientific OfficerDr. Olivier Danos Ph.D.

Executive VP & Chief Commercial OfficerDr. Ram Palanki Pharm.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RGNX

Regenxbio Inc

Upgrade your Finviz experience